Improving the Mood Disorder Questionnaire to Detect Bipolar II Disorder
Dear Editor:
The Mood Disorder Questionnaire (MDQ) (1) is a self-assessment screening tool for a broad diagnosis of the bipolar spectrum (that is, bipolar I [BD I], bipolar II [BD II], and bipolar not otherwise specified [BD NOS], according to DSM-IV criteria). It has 13 questions covering hypomania symptoms, clustering of symptoms, and impaired functioning. Its criteria for a diagnosis within the bipolar spectrum are more than 6 positive questions, plus clustering of symptoms, plus moderate-to-severe impairment. Compared with the Structured Clinical Interview for DSM-III-R (SCID), the MDQ had sensitivity of 73% and specificity of 90% for a bipolar spectrum diagnosis in clinical samples (1) and sensitivity of 28% and specificity of 97% in community samples (2) . According to the MDQ, community frequency of the bipolar spectrum was 3.4%-a figure similar to that achieved by adding figures reported in the DSM-IV (meaning underdiagnosis of BD II [3, 4] ). One limitation of the MDQ is the required moderate-to-severe impairment (5) . Because hypomania in BD II often shows improved functioning (6, 7) , the MDQ is biased against BD II and should be improved to better detect it. Using a semistructured interview focusing on past overactivity, clinicians probing for past hypomania found (with high interrater agreement) that BD II was present in approximately 50% of clinical and community samples of subjects with depression (8) (9) (10) (11) .
This study aimed to test the usefulness of the MDQ in a clinical sample and to modify it to increase its detection of BD II. In a private practice, 101 consecutively remitted outpatients with BD I, BD II, or major depressive disorder (MDD) were given the MDQ during follow-up visits. Soon after, they were interviewed with the SCID-Clinician Version (SCID-CV) (12) . The interviewer was blind to MDQ results. Setting and interview methods are reported in detail elsewhere (9, 13) . There were many more remitted BD (BD I and BD II) than MDD patients because BD patients were followed up more frequently.
Results
According to the MDQ, frequency of BD was 17.8% (n = 18). According to the SCID-CV, frequency of BD I was 16.8% (n = 17), frequency of BD II was 59.4% (n = 60), and frequency of MDD was 23.7% (n = 24). To test whether this big difference in BD frequency observed between the MDQ and the SCID-CV was related to the the MDQ's impairment criterion, calculations were remade after deleting it. The modified MDQ was called the MDQ7, indicating a cluster of at least 7 positive items. The MDQ7 found 65 cases of BD; of these, the SCID-CV identified 57 (87.8%) as BD (BD 1, 24.2%; BD II, 63.6%) Among the cases not identified by the MDQ7 (n = 33), 18 (54.2%) were classified by the SCID-CV as BD (BD I, 2.8%; BD II, 51.4%).
Using Stata statistical software (14) , we studied agreement between the MDQ, the MDQ7, and the SCID-CV. Comparing the MDQ and the SCID-CV for BD I, we found agreement = 79.2%, kappa = 0.27, and P = 0.0029. Comparing the MDQ and the SCID-CV for BD II, we found agreement = 36.6%, kappa = -0.13, and P = 0.9747. Next, we compared the MDQ7 and the SCID-CV for BD I, finding agreement = 49.5%, kappa = 0.16, and P = 0.0031. When we compared the MDQ7 and the SCID-CV for BD II, we found agreement = 58.4%, kappa = 0.11, and P = 0.1172. Then, we compared the MDQ and the SCID-CV for BD (BD I + BD II) and found agreement = 33.6%, kappa = 0.00, and P = 0.4328. Comparing the MDQ7 and the SCID-CV for BD (BD I + BD II), we found agreement = 73.2%, kappa = 0.36, and P = 0.0001. Logistic regression was used to study associations, sensitivity, and specificity. The MDQ was not significantly associated with SCID-CV BD (Odds Ratio = 1.1, z = 0.17, P = 0.866). The MDQ7 was associated with SCID-CV BD (Odds Ratio = 6.1, z = 3.5, P = 0.000), giving a sensitivity of 87.8% and a specificity of 45.7% for predicting SCID-CV BD.
The MDQ had much higher agreement with the SCID-CV for the detection of BD I, compared with BD II, and low agreement for the detection of BD (BD I + BD II). By contrast, the MDQ7 had high agreement with SCID-CV for the detection of BD. Because the MDQ is a screening tool for bipolar spectrum detection (which then needs to be followed by clinical evaluation), sensitivity is more important than specificity. The modified MDQ's high sensitivity for BD detection (specifically, modified by deleting the impairment criterion) means few false negatives, or few subjects lost for clinical evaluation (which would then lead to the final diagnosis). The high underdetection of BD II by the MDQ can thus be improved by deleting its impairment criterion.
Franco Benazzi, MD Forlí, Italy

Mnemonic for the Diagnosis of Hypomania Associated with Bipolar II Disorder
In the area of primary care psychiatry and general psychiatry, the 1990s could be termed "the decade of the antidepressants." This was a period of intense medical and public education focusing on depression as a legitimate, biologically based illness amenable to treatments with many newly available and different classes of antidepressants. This effort has helped alleviate the suffering of many patients and given clinicians-especially primary care physicians-new knowledge and tools to treat depressive illness. However, 15 years after the introduction of the first selective serotonin reuptake inhibitor (SSRI), fluoxetine, it is becoming apparent that antidepressants do not work for everyone: in controlled trials, the rate of symptom remission for antidepressant therapy is at best 50% (1, 2) . Of more concern is the observation that antidepressants can make some patients worse by introducing or worsening anxious, agitated, or restless states and sometimes inducing insomnia intermingled with racing thought (3, 4) . Emerging evidence suggests that these antidepressant activations may be a result of unrecognized bipolar disorder (BD), usually BD II, which is being increasingly recognized as a common mood disorder both in outpatient psychiatry (5) and in primary care (6) . Affected patients usually present in the depressed state, because their hypomanic episodes are typically elated and adaptive; patients suffering from depression lack specific recall of them (7) . Because patients lack recall of hypomanic episodes, recognizing bipolar illness has been problematic, even in psychiatric settings (8, 9) . There is an average delay of 8 to 12 years before an accurate diagnosis is made. To help identify possible hypomanic episodes in a depression patient's history, and thereby decrease the delay in accurate diagnosis, we have come up with a mnemonic incorporating the DSM-IV-R definition of hypomania. The mnemonic is HIGH-4, as follows: We believe that, by using this mnemonic to remind ourselves to look for the presence of hypomanic episodes in all depression patients in clinical settings, we can more accurately diagnose BD in a shorter time frame. This will allow us to use more appropriate therapies to treat BD patients and to avoid embarking on an antidepressant misadventure resulting in more suffering for our patients. In other words, when the patient is low, we should think HIGH-4! John F Chiu, MD, CCFP Pratap R Chokka, MD, FRCPC Edmonton, Alberta
Aripiprazole-Induced Improvement in Tardive Dyskinesia
Atypical antipsychotics, particularly clozapine, have been reported effective in the treatment of tardive dyskinesia (TD) (1) . We report the case of a patient with schizoaffective disorder who showed remarkable improvement in TD following treatment with aripiprazole (APZ).
Case Report
Mrs A, aged 41 years, suffered from chronic schizoaffective disorder of 20 years' duration and was admitted with psychotic exacerbation. The patient had been free of antipsychotics for the last 6 months but had significant TD in the form of choreoathetoid movement of her upper extremities and truncal dyskinesia. TD was first noticed about 2 years ago, while she was taking haloperidol. Discontinuation of haloperidol and subsequent sequential trials of risperidone, olanzapine, ziprasidone, and quetiapine did not improve the TD. Quetiapine exacerbated the TD and olanzapine, ziprasidone, and risperidone had to be discontinued owing to weight gain, EKG changes, and hyperprolactinemia,
